EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.

Dynamic Global Events (“DGE”) is proud to announce the 6th Clinical Trial Agreements Summit taking place August 21-22 in Philadelphia. This event wil ...

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our ...

In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide, according to the World ...

Alkermes PLC Annual cash flow by MarketWatch. View ALKS net cash flow, operating cash flow, operating expenses and cash dividends.

Fintel reports that on June 17, 2025, UBS upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Neutral to Buy. Analyst Price Forecast Suggests 39.18% Upside As of June 2, 2025, the average one ...

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $42.00. The company’s shares ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF – Research Report) and Alkermes (ALKS – Research Report). Confident I ...